Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. - Wikidata - wikimedia - TriplyDB

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

http://www.wikidata.org/entity/Q41257241

about

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.Antiretroviral Pharmacokinetics in Pregnant Women.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy.Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

P2860

Q33815637-712039C7-E765-4C99-A709-E4B915D31CA0 Q36887876-85A88E30-8B7F-452E-B38B-E6F98A75B50C Q37199763-D1AD59B9-F81E-42FF-8B92-44E7772F9A7F Q38571596-C2071BE5-D91D-4533-A6F5-1E0174E2A0D7 Q38868949-A9445ABA-26D4-4548-A0EB-67313C548AEA Q38872808-97E2DE7D-C53C-441F-8CC0-5A576EC33534 Q40041922-51641B50-8B30-4E3B-9BDA-34904E87FF5B Q42318291-D38F6B42-90BB-4339-BC7F-BCD1154683BB Q47548999-98AA3DFE-C38B-4FB9-BEFF-191A1E0FBB8A Q56762706-D3786925-FBF0-4C7F-BEF7-972C3AA6D736

P2860

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

http://www.wikidata.org/entity/Q41257241

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

@en

type

label

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

@en

prefLabel

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

@en

P1433

Q41257241-A69A0BA0-87F7-4BF9-9A26-69706D929BB1

P1476

Q41257241-78FC20DC-3D23-4E4C-AD3A-ED85759ED6F4

P2093

Q41257241-17F86BF5-046E-478E-B8DE-2676EA7DA3B0

Q41257241-185660D8-9E46-4259-8CB5-E2223715BBB5

Q41257241-1EBBF308-1EF3-4D97-96A0-CFC59666C03A

Q41257241-2107EF03-44A7-4DCC-9D05-B7A3B8A1D579

Q41257241-262E0DDD-0750-43DD-BAB2-81108C3DDCCB

Q41257241-39E8FB10-B522-46FE-9733-D47F64BA3563

Q41257241-3C9A1020-BF17-48B1-BA90-5936AFE607A7

Q41257241-4526AAA0-6672-4B25-B8E6-9DE147B51C44

Q41257241-49EF46DB-98F2-4CD9-B67D-73DB4AF11EE9

Q41257241-5FBCD22C-47D2-4690-B907-2908ED9D04F6

P2860

Q41257241-01E45DC7-D28F-45CB-B2D5-6364BC705885

Q41257241-0562DF34-100B-480D-AD68-80DBFF33A12E

Q41257241-10573346-6E4F-46DD-91D2-A717CEEAAEE7

Q41257241-116D100E-E516-4DE0-9DBE-9AB927A24020

Q41257241-1BBFB000-7DF1-4535-B72F-A473FE394C7C

Q41257241-4A7FB40C-DF56-4181-81E6-5D6AD6550A5F

Q41257241-55F4B83B-6883-43FA-A1BD-F11AC51CD72C

Q41257241-5D6CC730-73BA-4003-AE0A-3A54AED3F3D3

Q41257241-6D2CD7E9-5DB3-4CE9-909A-2285ABED5177

Q41257241-8D7989C9-D5B2-4BAD-8C4E-CD616FEA17FE

P304

Q41257241-CF299F2A-601F-4FDE-BA8D-2A01074D979E

P31

Q41257241-FE312804-EE39-4736-9D2A-AA99B0C8DD6A

P356

Q41257241-CFFF2511-B250-4D20-AF20-13BACD693961

P407

Q41257241-8B97EA5B-CFA2-4664-8CB4-2116B45C1307

P433

Q41257241-26796D4F-4986-4E8E-9215-AC94C56DE192

P478

Q41257241-84010424-2107-452E-934D-FE75BDE1C733

P577

Q41257241-80FF657F-15D0-47B9-85D4-4968A0BFC13D

P698

Q41257241-C11CE7E5-E493-4EF4-8920-FC1F6C915489

P356

P1433

Clinical Infectious Diseases

P1476

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

@en

P2093

Andrea Gingelmaier

http://www.w3.org/2001/XMLSchema#string

Angela P H Colbers

http://www.w3.org/2001/XMLSchema#string

Annette E Haberl

http://www.w3.org/2001/XMLSchema#string

Carlo Giaquinto

http://www.w3.org/2001/XMLSchema#string

Carmen Hidalgo-Tenorio

http://www.w3.org/2001/XMLSchema#string

David A Hawkins

http://www.w3.org/2001/XMLSchema#string

David M Burger

http://www.w3.org/2001/XMLSchema#string

Graham P Taylor

http://www.w3.org/2001/XMLSchema#string

Jelena Ivanovic

http://www.w3.org/2001/XMLSchema#string

José Moltó

http://www.w3.org/2001/XMLSchema#string

P2860

A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format

Raltegravir pharmacokinetics in neonates following maternal dosing

Raltegravir pharmacokinetics during pregnancy.

Clinical therapeutics in pregnancy.

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Combination antiretroviral use and preterm birth.

Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.

One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.

P304

809-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV366

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25944344

http://www.w3.org/2001/XMLSchema#string